PositiveID, a developer of airborne bio-threat detection systems for the U.S. homeland defense industry and creator of advanced technologies for rapid medical testing and diabetes management, has signed a license and teaming agreement with The Boeing Company.
Per the agreement, which includes a license fee to PositiveID of $2.5 million, Boeing has the exclusive license to manufacture and sell PositiveID’s M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector for the U.S. Department of Homeland Security’s (DHS) BioWatch Generation 3 opportunity, as well as other opportunities that may arise in the North American market.
PositiveID will retain exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing in the U.S. market, as well as keep the right to sell M-BAND units, reagents, and assays in international markets.
PositiveID’s M-BAND is a bioaerosol monitor with full capability to collect, process, detect, and analyze air samples for the detection of bacteria, viruses, and toxins. Results from individual M-BAND instruments are reported through a secure wireless network in real time to give an accurate and up to date status. The M-BAND touts significant hardiness, operating from -25 to 125 degrees Fahrenheit, for both indoor and outdoor settings. Toxin analysis takes approximately 40 minutes.
For more information, visit www.PositiveIDCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment